Sign in

VRAX on Nasdaq

Virax Biolabs Group Ltd

Virax Biolabs Group Ltd is an exempted company.2 It is headquartered in George Town, Cayman Islands.2 Its shares trade on Nasdaq under the symbol VRAX.2

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

  • TickerVRAX on Nasdaq2
  • IndustryIn Vitro & In Vivo Diagnostic Substances2
  • HeadquartersGeorge Town, Cayman Islands2
  • Incorporated inCayman Islands3
  • Business addressBiocity Glasgow, Bo'Ness Road, Newhouse, Lanarkshire, X0 Ml1 5Uh3
  • Filer categoryNon-accelerated filer, Emerging growth company3
  • Legal formCorporation2
  • LEI25490017YHIJPOXAXI932
  • StatusActive2
  • LEI statusIssued and current2
  • Registered addressC/O Ogier Global (Cayman) Limited, KY1-9009 George Town, Cayman Islands2
  • Registered withGeneral Registry, OC-3804402

See how the biggest companies compare on our leaderboards

Our legal name is Virax Biolabs Group Limited, and our commercial name is “Virax Biolabs.” We are an exempted company with limited liability incorporated under the laws of the Cayman Islands. Our principal executive offices are located at BioCity Glasgow, Bo’Ness Road, Newhouse, Lanarkshire, ML1 5UH. Our telephone number is +44 020 7788 7414.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Gross profit56-$53.1K in 2025+463% since 2021
-$100.0K-$50.0K0$50.0K$100.0K2021: -$9.4K-$9.4K20212023: -$1.4K-$1.4K2023−86%2024: $50.6K$50.6K20242025: -$53.1K-$53.1K2025
Operating income576-$6.2M in 2025+856% since 2021
-$8.0M-$6.0M-$4.0M-$2.0M02021: -$644.5K-$644.5K20212022: -$1.7M-$1.7M2022+169%2023: -$5.7M-$5.7M2023+231%2024: -$6.5M-$6.5M2024+13%2025: -$6.2M-$6.2M2025−5%
Net income576-$6.1M in 2025+802% since 2021
-$8.0M-$6.0M-$4.0M-$2.0M02021: -$672.9K-$672.9K20212022: -$1.7M-$1.7M2022+160%2023: -$5.5M-$5.5M2023+212%2024: -$6.7M-$6.7M2024+23%2025: -$6.1M-$6.1M2025−10%

Every line of the income statement as filed: the last 3 fiscal years, latest first.8

Period ending2026-03-312025-03-312024-03-31
Revenue$12.4K$6.3K$156.4K
Cost of revenue$4.7K$59.4K$105.8K
Gross profit (loss)$7.7K-$53.1K$50.6K
General and administrative$2.7M$4.0M$4.6M
Research & development$3.7M$2.0M$1.6M
Impairment of intangible asset$0$0$390.4K
Total operating expenses$6.4M$6.0M$6.6M
Operating loss-$6.4M-$6.1M-$6.5M
Interest expense, net-$61.8K-$58.2K-$26.9K
Other income (expense), net$33$17.2K-$215.8K
Foreign currency gain (loss), net$529.0K-$86.1K$29.2K
Total other income (expense), net$467.3K-$127.1K-$213.4K
Loss before income taxes-$5.9M-$6.2M-$6.7M
Income tax benefit-$900.2K-$136.7K$0
Net loss-$5.0M-$6.1M-$6.7M
Net loss attributable to non-controlling interest-$8.4K-$6.0K-$5.6K
Net loss attributable to Virax Biolabs shareholders-$5.0M-$6.1M-$6.7M
Foreign currency adjustment$422.6K-$110.4K-$3.6K
Total Comprehensive loss-$5.5M-$6.0M-$6.7M
Comprehensive loss attributable to non-controlling interest-$8.4K-$6.0K-$5.6K
Comprehensive loss attributable to Virax Biolabs shareholders-$5.4M-$6.0M-$6.7M
Ordinary shares397.6K shares149.2K shares80.3K shares
Diluted ordinary shares397.6K shares149.2K shares80.3K shares
Basic net loss per share - Ordinary shares-$12.64-$40.62-$83.90
Diluted net loss per share - Ordinary shares-$12.64-$40.62-$83.90

Compare Virax Biolabs Group Ltd with another company

Corporate structure

Virax Biolabs Group Ltd sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Virax Biolabs Group Ltd

  • Virax Biolabs Group Ltd George Town, Cayman Islands

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Virax Biolabs Group Ltd reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$1.2M6 Mar 31, 2025$897.6K6 Mar 31, 2024+36.6%
Operating-lease assets (leased space)$306.7K6 Mar 31, 2025$206.1K6 Mar 31, 2024+48.8%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$4.2M6 Mar 31, 2025$3.6M6 Mar 31, 2024+17.8%

Inventory

ItemLatestA year beforeChange
Inventory, total$94.7K6 Mar 31, 2025$60.4K6 Mar 31, 2024+56.8%

Leadership

Who has led Virax Biolabs Group Ltd, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. James Alexander Cunliffe Foster2026–now

Chief financial officer

  1. Jason Davis2026–now

Chief operating officer

  1. Nigel William McCracken2026–now
Board members and other officers (2)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive Officer, DirectorMark Alexander Cunliffe Ternouth named Oct 17, 202314
  • Executive Officer, DirectorCameron Alexander Cunliffe Shaw named Mar 15, 202315
  • Executive OfficerMark Maurice Ternouth named Mar 15, 202315
  • Executive OfficerTomasz Maurice George named Mar 15, 202315
  • DirectorEvan Norton named Dec 18, 202516
  • DirectorNelson Haight named Dec 18, 202516
  • DirectorYair Erez named Dec 18, 202516
  • DirectorEvan Alexander Cunliffe Norton named Mar 15, 2023 to Oct 17, 202314
  • DirectorNelson Maurice Haight named Mar 15, 2023 to Oct 17, 202314
  • DirectorYair Alexander Cunliffe Erez named Mar 15, 2023 to Oct 17, 202314

Former names

  • Virax Biolabs (Cayman) LtdDec 27, 2021 to Dec 27, 20213

Timeline

  1. Mar 18, 2026New chief executive James Alexander Cunliffe Foster becomes CEO10
  2. Sep 2, 2021Founded Virax Biolabs Group Ltd is founded2

Filings

157 filings to the SEC since October 2021: 5 annual reports, 6 insider forms, 8 large holders, 3 private raises, 135 other. The latest 20:

  1. Oct 9, 20266-K EDGAR
  2. Sep 10, 2026424B3 EDGAR
  3. Sep 4, 20266-K EDGAR
  4. Sep 4, 2026424B5 EDGAR
  5. Sep 3, 2026EFFECT EDGAR
  6. Sep 2, 2026F-3/A EDGAR
  7. Aug 26, 20266-K EDGAR
  8. Aug 18, 20266-K EDGAR
  9. Jul 31, 20266-K EDGAR
  10. Jul 24, 2026F-3 EDGAR
  11. Jul 16, 20266-K EDGAR
  12. Jul 10, 20266-K EDGAR
  13. Jul 9, 20266-K EDGAR
  14. Jul 6, 202620-F EDGAR
  15. Jun 24, 20266-K EDGAR
  16. Jun 12, 20266-K EDGAR
  17. May 26, 20266-K EDGAR
  18. May 22, 20266-K EDGAR
  19. May 15, 2026SCHEDULE 13G/A EDGAR
  20. Apr 14, 20266-K EDGAR

The 157 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$11.2M 2023–2025
Money received by yearMoney received by year, 2023–2025: $11.2M in all. Private raises (Form D) $11.2M.$0$2M$4M$6M$8M2023 · Private raises (Form D): $6.2M202320242025 · Private raises (Form D): $5.0M2025
Figures by year
YearPrivate raises (Form D)Total
2025$5.0M$5.0M
2023$6.2M$6.2M

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. Dec 3, 2025Raised $5 million in a private offering of securities16 Form D: 1 investor so far Form D
  2. Oct 12, 2023Raised $2.1 million in a private offering of equity14 Form D: 1 investor so far Form D
  3. Mar 10, 2023Raised $4 million in a private offering of equity15 Form D: 1 investor so far Form D

SEC filer profile

How Virax Biolabs Group Ltd is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARVirax Biolabs Group Ltd1
  • CIK0001885827
  • Filer statusNon-accelerated filer an emerging growth company; not a shell company4
  • Incorporated inCayman Islands4
  • Fiscal year endsMarch 311
  • Industry code (SIC)2835 In Vitro & In Vivo Diagnostic Substances1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business addressBiocity Glasgow, Bo'Ness Road, Newhouse, Lanarkshire, X0 ML1 5UH1
  • Phone44 020 7788 74141
  • Shares outstanding579,218 shares as of Mar 31, 20264
  • AuditorReliant CPA PC, Newport Beach, CA PCAOB ID 6906; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceDec 27, 20211
  • Filings157 in all: 6-K (73), CORRESP (12), UPLOAD (10), 3 (6), 424B3 (6), EFFECT (6), F-1/A (6), 20-F (5)1
    All 26 form types

    424B5 (4), SCHEDULE 13G/A (4), D (3), F-1 (3), F-3 (3), FWP (2), NT 20-F (2), SCHEDULE 13G (2), 424B4 (1), 8-A12B (1), CERT (1), DRS (1), DRS/A (1), DRSLTR (1), F-3/A (1), S-8 (1), SC 13G (1), SC 13G/A (1)

  • Latest filingsAnnual report (20-F) Jul 6, 2026

Securities registered for trading

ClassSymbolExchange
ordinary shares, par value $0.025 per shareVRAXNasdaq

From the cover page of the 20-F filed Jul 6, 2026 (Section 12(b) of the Exchange Act).4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18